Adenovirus News and Research

RSS
Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.
Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

Researchers discover how vaccine-induced immune thrombotic thrombocytopenia happens

Researchers discover how vaccine-induced immune thrombotic thrombocytopenia happens

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

Is the SARS-CoV-2 delta variant threatening vaccine efficacy?

Is the SARS-CoV-2 delta variant threatening vaccine efficacy?

More evidence that mixing COVID-19 vaccines may help elicit a robust immune response

More evidence that mixing COVID-19 vaccines may help elicit a robust immune response

Nanotechnology and the fight against COVID-19

Nanotechnology and the fight against COVID-19

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Long COVID has low prevalence in school-age children, UK study suggests

Long COVID has low prevalence in school-age children, UK study suggests

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

The SARS-CoV-2 virus and its vaccines pose unique challenges

The SARS-CoV-2 virus and its vaccines pose unique challenges

New insight into SARS-CoV-2 mRNA vaccine breakthrough infections

New insight into SARS-CoV-2 mRNA vaccine breakthrough infections

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

Mouse-adapted SARS-CoV-2 and simian adenovirus vector advance COVID-19 vaccine research

Study details the treatment of COVID-19 vaccine-associated myocarditis-like illness in 7 patients

Study details the treatment of COVID-19 vaccine-associated myocarditis-like illness in 7 patients

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

Researchers examine the importance of time after COVID-19 vaccination

Researchers examine the importance of time after COVID-19 vaccination

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern

New Astra-Zeneca B.1.351 vaccine AZD2816 strongly immunogenic against multiple SARS-CoV-2 variants of concern